TY  - JOUR
PY  - 2016//
TI  - Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis
JO  - Journal of psychopharmacology
A1  - Nia, Anahita Bassir
A1  - Medrano, Benjamin
A1  - Perkel, Charles
A1  - Galynker, Igor
A1  - Hurd, Yasmin L.
SP  - 1321
EP  - 1330
VL  - 30
IS  - 12
N2  - BACKGROUND: Synthetic cannabinoids (SC) use has had a dramatic increase in recent years, but data regarding their adverse effects on mental health is limited. In this study, we compared clinical presentations of SC users with cannabis users in a psychiatric inpatient setting. <br><br>METHODS: Digital charts of all patients who were admitted to a dual diagnosis psychiatric unit in one year were reviewed. Patients who had any current substance use disorder were categorized in four groups: (1) SC use and cannabis use (SC+MJ+), (2) SC use without cannabis use (SC+MJ-), (3) cannabis use without SC use (SC-MJ+), and (4) No SC or cannabis use (SC-MJ-). <br><br>RESULTS: A total of 594 charts were included. SC+MJ- patients had significantly more psychotic symptoms (OR: 4.44, 95% CI: 1.98-9.94), followed by SC+MJ+ (OR: 3.61, 95% CI: 1.87-6.97) and SC-MJ+ (OR: 1.87, 95%CI: 1.33-2.64) patients. The SC+MJ- group also had more agitation and aggression was most prominent in SC+MJ+ subjects. Multivariate analyses showed that the psychiatric associations of SC and cannabis use remained significant even after controlling for potential confounds such as other substance use. <br><br>CONCLUSIONS: The prominent psychiatric features of SC users as compared to cannabis users in an inpatient setting are psychotic presentations and agitation, which have important treatment implications.<br><br>© The Author(s) 2016.<p />  <p>Language: en</p>
LA  - en
SN  - 0269-8811
UR  - http://dx.doi.org/10.1177/0269881116658990
ID  - ref1
ER  -